 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
21 News |  |
- | Ad-SGE-REIC - Momotaro / Gene
Journal, PD(L)-1 Biomarker, IO biomarker: PD-1 blockade augments CD8 T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer. (Pubmed Central) - Feb 8, 2023
Additionally, in Egfr-mutant lung cancer, this effect was enhanced by PD-1 blockade. These findings pave the way to establish a novel combined immunotherapy strategy with Ad-SGE-REIC and anti-PD-1 antibody for lung cancer with a non-inflamed TME.
- | Avastin (bevacizumab) / Roche, Ad-SGE-REIC - Momotaro / Gene
Journal: Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis. (Pubmed Central) - Sep 2, 2022
These results suggest that the combination therapy of Ad-SGE-REIC and bevacizumab exerts anti-glioma effects by suppressing the angiogenesis and invasion of tumors. Combined Ad-SGE-REIC and bevacizumab might be a promising strategy for the treatment of malignant glioma.
- | Ad-SGE-REIC - Momotaro / Gene
Enrollment closed, Trial completion date, Trial primary completion date: MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma (clinicaltrials.gov) - Jun 16, 2022
P2, N=12, Active, not recruiting, Sponsor: Momotaro-Gene Inc.
Combined Ad-SGE-REIC and bevacizumab might be a promising strategy for the treatment of malignant glioma. Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Sep 2020 --> Dec 2022
- | Ad-SGE-REIC - Momotaro / Gene
Journal, IO biomarker: Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading. (Pubmed Central) - May 24, 2022
An immune monitoring study was conducted using the serum samples on an adenovirus-mediated REIC/Dkk-3 gene therapy clinical trial that showed a successful clinical response in metastatic castration-resistant prostate cancer...Thus, quantitative monitoring of anti-CTA antibody biomarkers can be used to evaluate the cancer-immunity cycle. A quality-certified serum autoantibody monitoring system is a powerful tool for developing and evaluating cancer immunotherapy.
- | cisplatin / Generic mfg.
Journal: Promising gene therapy using an adenovirus vector carrying REIC/Dkk-3 gene for the treatment of biliary cancer. (Pubmed Central) - Jul 14, 2021
Ad-SGE-REIC induced apoptosis and inhibited tumor growth in biliary cancer cells. REIC/Dkk-3 gene therapy using Ad-SGE-REIC is an attractive therapeutic tool for biliary cancer.
- | MTG-201 - Momotaro / Gene
Preclinical, Journal: Dkk3/REIC, an N-glycosylated Protein, Is a Physiological Endoplasmic Reticulum Stress Inducer in the Mouse Adrenal Gland. (Pubmed Central) - Apr 2, 2021
Forced expression of Dkk3 resulted in the induction of distinct levels of reporter expression, showing the UPR initiated by the ER membrane proteins of activating transcription factor 6 (ATF6) and inositol-requring enzyme 1 (IRE1). Thus, it is possible that Dkk3 is a physiological ER stressor in the mouse adrenal gland.
- || MTG-201 - Momotaro / Gene
Clinical, P1/2 data, Journal: Study protocol of a Phase I/IIa clinical trial of Ad-SGE-REIC for treatment of recurrent malignant glioma. (Pubmed Central) - Oct 8, 2020
The secondary end points are the objective response rate and immunological assessment. Use of Ad-SGE-REIC will help to improve the prognosis of patients with malignant brain tumors.
- || Ad-SGE-REIC - Momotaro / Gene
Trial completion: Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - Sep 4, 2020
P1/2, N=28, Completed, Sponsor: Momotaro-Gene Inc.
Use of Ad-SGE-REIC will help to improve the prognosis of patients with malignant brain tumors. Active, not recruiting --> Completed
- MTG-201 - Momotaro / Gene
The current status of Ad-SGE-REIC gene therapy for malignant glioma (Ballroom Lawn) - Oct 29, 2019 - Abstract #SNO2019SNO_965;
We demonstrated the anti-glioma effect of Ad-SGE-REIC. We will start a phase I/IIa clinical trial of Ad-SGE-REIC for the treatment of recurrent malignant glioma.
- | Ad-SGE-REIC - Momotaro / Gene
Trial completion date: Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - Oct 22, 2019
P1/2, N=28, Active, not recruiting, Sponsor: Momotaro-Gene Inc.
We will start a phase I/IIa clinical trial of Ad-SGE-REIC for the treatment of recurrent malignant glioma. Trial completion date: Jun 2019 --> Mar 2020
- | Ad-SGE-REIC - Momotaro / Gene
Enrollment open, PD(L)-1 Biomarker: MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma (clinicaltrials.gov) - Oct 7, 2019
P2, N=12, Recruiting, Sponsor: Momotaro-Gene Inc.
Trial completion date: Jun 2019 --> Mar 2020 Not yet recruiting --> Recruiting
- | Ad-SGE-REIC - Momotaro / Gene
New P2 trial, PD(L)-1 Biomarker: MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma (clinicaltrials.gov) - Jul 8, 2019
P2, N=12, Not yet recruiting, Sponsor: Momotaro-Gene Inc.
- | Ad-SGE-REIC - Momotaro / Gene
Enrollment closed, Trial completion date: Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - Mar 8, 2019
P1/2, N=28, Active, not recruiting, Sponsor: Momotaro-Gene Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019
- Ad-SGE-REIC - Momotaro / Gene
Trial completion date, Trial primary completion date: Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - Mar 27, 2018
P1/2, N=30, Recruiting, Sponsor: Momotaro-Gene Inc.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019 Trial completion date: Dec 2016 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Sep 2018
- Ad-SGE-REIC - Momotaro / Gene
Trial primary completion date: Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - Dec 30, 2015
P1/2, N=30, Recruiting, Sponsor: Momotaro-Gene Inc.
Trial completion date: Dec 2016 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Sep 2018 Trial primary completion date: Dec 2015 --> Dec 2016
- | Ad-SGE-REIC - Momotaro / Gene
Enrollment open, Trial primary completion date: Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - Oct 10, 2014
P1/2, N=30, Recruiting, Sponsor: Momotaro-Gene Inc.
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2015 --> Dec 2015
- | Ad-SGE-REIC - Momotaro / Gene
New P1/2 trial: Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - Aug 20, 2013
P1/2, N=30, Not yet recruiting, Sponsor: Momotaro-Gene Inc.